Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Baebies

Baebies develops and commercializes products and services that enable early disease detection and comprehensive diagn... read more Featured Products: More products

Download Mobile App




First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

By LabMedica International staff writers
Posted on 08 May 2025

Heparin dosing requires careful management to avoid both bleeding and clotting complications. More...

In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%, with bleeding occurring in over one-third of patients. Anti-Factor Xa tests, the preferred method for monitoring heparin therapy, are typically conducted in central labs and take over an hour to return results, leading to delays in crucial dosing decisions. Now, a new point-of-care heparin monitoring assay designed for patients receiving unfractionated or low molecular weight heparin offers results in under 15 minutes from just 50 µL of whole blood.

Baebies (Durham, NC, USA) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Anti-Factor Xa test on the FINDER platform. This designation highlights the test’s potential to bring heparin monitoring directly to the patient, enabling faster and more efficient dose management in critical care settings. Unlike existing tests, the FINDER Anti-Factor Xa Test requires no centrifugation and can be performed directly at the point of care or in a central lab, providing results within minutes. The test addresses a life-threatening condition, offers substantial improvements over current methods, introduces breakthrough technology where no approved alternatives exist, and aligns with the FDA’s Breakthrough Device criteria, ultimately benefiting patients.

"This designation provides priority FDA review and dedicated regulatory guidance, accelerating our efforts to bring the test to market," said Richard West, Founder and CEO of Baebies. "It positions FINDER to expand rapidly into the multi-billion-dollar coagulation testing space."


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.